Vistin Pharma Management
Management criteria checks 4/4
Vistin Pharma's CEO is Magnus Tolleshaug, appointed in Feb 2022, has a tenure of 2.75 years. total yearly compensation is NOK2.24M, comprised of 81% salary and 19% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth NOK1.86M. The average tenure of the management team and the board of directors is 2.8 years and 6.5 years respectively.
Key information
Magnus Tolleshaug
Chief executive officer
NOK 2.2m
Total compensation
| CEO salary percentage | 81.0% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.8yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors
Sep 18
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)
Sep 09Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)
Aug 25Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First
Mar 15We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?
Jan 29The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It
Jan 08Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?
Dec 16Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NOK 61m |
| Jun 30 2024 | n/a | n/a | NOK 68m |
| Mar 31 2024 | n/a | n/a | NOK 56m |
| Dec 31 2023 | NOK 2m | NOK 2m | NOK 46m |
| Sep 30 2023 | n/a | n/a | NOK 45m |
| Jun 30 2023 | n/a | n/a | NOK 14m |
| Mar 31 2023 | n/a | n/a | NOK 7m |
| Dec 31 2022 | NOK 3m | NOK 2m | -NOK 5m |
| Sep 30 2022 | n/a | n/a | -NOK 15m |
| Jun 30 2022 | n/a | n/a | -NOK 7m |
| Mar 31 2022 | n/a | n/a | NOK 929k |
| Dec 31 2021 | NOK 2m | NOK 1m | NOK 25m |
| Sep 30 2021 | n/a | n/a | NOK 26m |
| Jun 30 2021 | n/a | n/a | NOK 30m |
| Mar 31 2021 | n/a | n/a | NOK 43m |
| Dec 31 2020 | NOK 2m | NOK 1m | -NOK 97m |
Compensation vs Market: Magnus's total compensation ($USD201.47K) is below average for companies of similar size in the Norwegian market ($USD300.00K).
Compensation vs Earnings: Magnus's compensation has been consistent with company performance over the past year.
CEO
Magnus Tolleshaug
2.8yrs
Tenure
NOK 2,238,000
Compensation
Mr. Magnus Tolleshaug Serves as a Commercial Director at Vistin Pharma ASA and served as its Interim Chief Executive Officer since February 16, 2022 until January 1, 2024 and serves as its Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Commercial Officer & Commercial Director | 2.8yrs | NOK 2.24m | 0.17% NOK 1.9m | |
| Chief Financial Officer | 4.7yrs | NOK 2.34m | no data | |
| Chief Operating Officer | less than a year | NOK 2.18m | 0.17% NOK 1.9m | |
| Director of Technical Service & Sales | no data | no data | no data |
2.8yrs
Average Tenure
Experienced Management: VISTN's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | 4.4yrs | NOK 441.00k | no data | |
| Independent Director | 9.8yrs | NOK 210.00k | 3.51% NOK 38.6m | |
| Independent Director | 6.5yrs | NOK 231.00k | no data | |
| Independent Director | 4.4yrs | NOK 210.00k | no data | |
| Employee Representative Director | 9.8yrs | NOK 210.00k | 0.0050% NOK 54.5k | |
| Independent Director | 4.5yrs | NOK 210.00k | no data | |
| Employee Representative Director | 7.1yrs | NOK 210.00k | no data |
6.5yrs
Average Tenure
61yo
Average Age
Experienced Board: VISTN's board of directors are considered experienced (6.5 years average tenure).